Search Results

8 results

  1. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 13

    Importance of e-liquid preparation and stability characterization for a combinatorial safety assessment approach of flavors in e-liquids

    GLABASNIA A.(1); DIANA P.(1); SMITH C.(2); MILLER J.H.(2); BIASIOLI M.(1); FRAUENDORFER F.(1); SCIUSCIO D.(1); MARTIN E.(1); POSPISIL P.(1); GUY P.(1); VANSCHEEUWIJCK P.(1); HOENG J.(1); KUMAR A.(2); LEE K.M.(2)
    (1) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (2) Altria Client Services LLC, Richmond, VA, U.S.A.
    Numerous flavorings are generally recognized as safe for use in food, but there is limited information available to evaluate their potential toxicity by inhalation. Consequently, gaining information on individual flavor safety levels is of significant ...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 40 (also presented at TSRC 2019)

    A seven-month systems toxicology inhalation study in C57BL/6 mice demonstrates reduced pulmonary inflammation and emphysema following smoking cessation or switching to e-vapor aerosol exposures

    KUMAR A.(1); KOGEL U.(2); TALIKKA M.(2); SKOWRONEK A.(3); HOENG J.(2); PEITSCH M.C.(2); LEE K.M.(1)
    (1) Altria Client Services LLC, Richmond, VA, U.S.A.; (2) Philip Morris Products S.A., R&D, Neuchâtel, Switzerland; (3) Battelle, West Jefferson, OH, U.S.A.
    Cigarette smoking causes lung cancer, emphysema, and other serious diseases. While cessation remains the most effective approach to minimize smoking-related diseases, alternative nicotine delivery products that limit the generation of combustion by ...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 49

    The CORESTA in vitro test battery for combustible tobacco products: update from the 2004 Rationale and Strategy Report

    LEE K.M.(1); JORDAN K.G.(2); WIECZOREK R.(3); MOENNIKES O.(4); CLEMENTS J.(5); CROOKS I.(6); HASHIZUME T.(7); MILLER J.(8); WEBER E.(9); YOSHINO K.(7)
    (1) Altria Client Services, Richmond, VA, U.S.A.; (2) RAI Services Company, Winston-Salem, NC, U.S.A.; (3) Imperial Brands, Reemtsma Cigarettenfabriken GmbH, Hamburg, Germany; (4) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (5) Covance Laboratories Ltd, Harrogate, U.K.; (6) British American Tobacco (Investments) Ltd, R&D, Southampton, U.K.; (7) Japan Tobacco Inc., Yokohama, Kanagawa, Japan; (8) JT International SA, Geneva, Switzerland; (9) Ökolab, Vienna, Austria
    In 2004, the CORESTA In Vitro Toxicity Task Force issued a rationale and strategy report, commonly known as “the CORESTA in vitro test battery guideline”. The goals of this guideline were to: 1) develop the rationale and strategy for conducting in vitro ...
  4. TSRC, Tob. Sci. Res. Conf., 2019, 73, abstr. 022 (also presented at CORESTA SSPT2019)

    A seven-month systems toxicology inhalation study in C57BL/6 mice demonstrates reduced pulmonary inflammation and emphysema following smoking cessation or switching to e-vapor aerosol exposures

    KUMAR A.(1); KOGEL U.(2); TALIKKA M.(2); HOENG J.(2); PEITSCH M.(2); SKOWRONEK A.(3); LEE K.M.(1)
    (1) Altria Client Services, Richmond, VA, USA; (2) Philip Morris International, Neuchâtel, Switzerland; (3) Battelle, West Jefferson, OH, USA
    Cigarette smoking causes lung cancer, emphysema, and other serious diseases. While cessation remains the most effective approach to minimize smoking-related diseases, alternative nicotine delivery products that limit the generation of combustion by ...
  5. TSRC, Tob. Sci. Res. Conf., 2019, 73, abstr. 103

    Preclinical testing of flavors in e-vapor products - Part 1: Selection of representative flavor mixtures for toxicological evaluations using a structural grouping approach

    EHMAN K.D.(1); LANGSTON T.B.(1); KUMAR A.(1); LEE K.M.(1); SCIUSCIO D.(2); VANSCHEEUWIJCK P.(2); HOENG J.(2)
    (1) Altria Client Services, Richmond, VA, USA; (2) PMI R&D, Neuchâtel, Switzerland
    A variety of flavor ingredients are used in potentially reduced-risk tobacco or nicotine products, including e-vapor products. For this work, the ingredients were initially evaluated for quality and purity, which included assessment of food grade and GRAS ...
  6. TSRC, Tob. Sci. Res. Conf., 2019, 73, abstr. 104

    Preclinical testing of flavors in e-vapor products - Part 2: Preparation and stability characterization of representative flavor mixtures

    SMITH C.R.(1); MILLER J.H. IV(1); SHAH N.(1); KUMAR A.(1); LEE K.M.(1); FRAUENDORFER F.(2); GUY P.(2); DIANA P.(2); GLABASNIA A.(2)
    (1) Altria Client Services, Richmond, VA, USA; (2) PMI R&D, Neuchâtel, Switzerland
    GLP guidelines require the characterization of test articles for preclinical biological studies to ensure the identity and composition are consistent from batch to batch and throughout the testing period. For e-vapor products, this would suggest that the ...
  7. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 30

    Effects of exposure to e-cigarette aerosols compared with cigarette smoke on 3D human buccal and small airway cultures: a systems toxicology assessment

    ISKANDER A.(1); STEINER S.(1); MAJEED S.(1); KONDYLIS A.(1); XIANG Yang(1); ZANETTI F.(1); FRENTZEL S.(1); MARTIN F.(1); PEITSCH M.C.(1); DOSHI U.(2); McKINNEY W.J.(2); LEE K.M.(2); HOENG J.(1)
    (1) Philip Morris Products S.A. (part of Philip Morris International group of companies), PMI R&D, Neuchâtel, Switzerland; (2) Altria Client Services LLC, Research, Development & Regulatory Affairs, Richmond VA, U.S.A.
    Considerable attention has been given toward the reduced risk potential of e-cigarettes (e-cigs). Most in vitro studies have focused on testing e-liquid formulations directly on submerged 2D cultures. Here, we examined the effects of exposure to the whole ...
  8. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 61

    A 6-month inhalation study in Apoe-/- mice to investigate cardiovascular and respiratory exposure effects of e-vapor aerosols compared with cigarette smoke

    WONG Ee Tsin(1); SZOSTAK J.(2); KRISHNAN S.(1); TAN Wei Teck(1); SEOW E.(1); TENG C.(1); LEE K.M.(3); ZHANG Jingjie(3); McKINNEY W.J.(3); PEITSCH M.C.(2); VANSCHEEUWIJCK P.(2); HOENG J.(2)
    (1) Philip Morris International Research Laboratories Pte. Ltd., (part of Philip Morris International group of companies), PMI R&D, Singapore; (2) Philip Morris Products S.A. (part of Philip Morris International group of companies), PMI R&D, Neuchâtel, Switzerland; (3) Altria Client Services LLC, Richmond, VA, U.S.A.
    Chronic exposure to cigarette smoke is a risk factor for the development and progression of cardiovascular disease and chronic obstructive pulmonary disease. Considerable attention has been given towards the potential reduced harm of e cigarettes (e cigs) ...